Opiant Pharmaceuticals Inc (NASDAQ:OPNT) Director Michael Sinclair sold 60,000 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $12.52, for a total transaction of $751,200.00.
OPNT opened at $15.90 on Thursday. The company has a 50-day moving average of $13.97 and a 200-day moving average of $13.07. The company has a market capitalization of $63.99 million, a P/E ratio of -2.24 and a beta of 0.32. Opiant Pharmaceuticals Inc has a 1-year low of $9.98 and a 1-year high of $23.33.
Opiant Pharmaceuticals (NASDAQ:OPNT) last released its earnings results on Thursday, August 8th. The technology company reported $0.31 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.86. The company had revenue of $6.78 million during the quarter, compared to the consensus estimate of $3.91 million. Opiant Pharmaceuticals had a negative net margin of 11.78% and a negative return on equity of 12.74%. As a group, sell-side analysts expect that Opiant Pharmaceuticals Inc will post 1.05 earnings per share for the current year.
Several research firms have recently weighed in on OPNT. Northland Securities reissued a “buy” rating on shares of Opiant Pharmaceuticals in a research report on Friday, August 2nd. ValuEngine raised shares of Opiant Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 6th. Finally, TheStreet raised shares of Opiant Pharmaceuticals from a “d” rating to a “c-” rating in a research report on Friday, August 30th.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
Featured Article: How a Strangle Strategy is different from a Straddle Strategy
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.